Total Payments
$18,664
2024 Payments
$2,880
Companies
13
Transactions
107
Medicare Patients
361
Medicare Billing
$33,087
Payment Breakdown by Category
Travel$9,026 (48.4%)
Research$3,674 (19.7%)
Food & Beverage$3,065 (16.4%)
Consulting$2,900 (15.5%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Travel and Lodging | $9,026 | 32 | 48.4% |
| Unspecified | $3,674 | 29 | 19.7% |
| Food and Beverage | $3,065 | 43 | 16.4% |
| Consulting Fee | $2,900 | 3 | 15.5% |
Payments by Type
General
$14,991
78 transactions
Research
$3,674
29 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $6,471 | 25 | $0 (2024) |
| UCB, Inc. | $3,472 | 19 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $1,962 | 10 | $0 (2018) |
| Alexion Pharmaceuticals, Inc. | $1,649 | 7 | $0 (2023) |
| UCB SA | $1,537 | 9 | $0 (2024) |
| SANOFI US SERVICES INC. | $1,220 | 14 | $0 (2018) |
| AstraZeneca UK Limited | $1,075 | 6 | $0 (2024) |
| Celgene Corporation | $453.99 | 7 | $0 (2019) |
| Amgen Inc. | $256.92 | 3 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $203.80 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,880 | 19 | UCB SA ($1,537) |
| 2023 | $6,456 | 35 | UCB, Inc. ($3,377) |
| 2022 | $311.38 | 3 | Amgen Inc. ($116.00) |
| 2019 | $306.18 | 5 | Celgene Corporation ($266.18) |
| 2018 | $7,136 | 38 | GlaxoSmithKline, LLC. ($4,981) |
| 2017 | $1,575 | 7 | Novartis Pharmaceuticals Corporation ($1,328) |
All Payment Transactions
107 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/30/2024 | UCB SA | — | Travel and Lodging | Cash or cash equivalent | $79.84 | General |
| 10/06/2024 | AstraZeneca UK Limited | SAPHNELO (Biological) | Travel and Lodging | In-kind items and services | $115.60 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 10/06/2024 | AstraZeneca UK Limited | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $74.20 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 10/06/2024 | AstraZeneca UK Limited | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $47.70 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 10/06/2024 | AstraZeneca UK Limited | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $43.72 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 10/06/2024 | AstraZeneca UK Limited | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $23.85 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 10/05/2024 | AstraZeneca UK Limited | SAPHNELO (Biological) | Travel and Lodging | In-kind items and services | $769.70 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 10/03/2024 | UCB SA | — | Travel and Lodging | In-kind items and services | $841.95 | General |
| 10/03/2024 | UCB SA | — | Travel and Lodging | In-kind items and services | $151.25 | General |
| 10/03/2024 | UCB SA | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 10/03/2024 | UCB SA | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 10/03/2024 | UCB SA | — | Food and Beverage | In-kind items and services | $25.00 | General |
| 10/03/2024 | UCB SA | — | Food and Beverage | In-kind items and services | $25.00 | General |
| 10/02/2024 | UCB SA | — | Travel and Lodging | In-kind items and services | $179.18 | General |
| 10/02/2024 | UCB SA | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 04/02/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $115.00 | General |
| 04/02/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $35.00 | General |
| 01/11/2024 | GlaxoSmithKline, LLC. | — | — | Cash or cash equivalent | $82.21 | Research |
| Study: A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP, MUL | ||||||
| 01/11/2024 | GlaxoSmithKline, LLC. | — | — | Cash or cash equivalent | $35.72 | Research |
| Study: A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP, MUL | ||||||
| 12/06/2023 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $43.28 | General |
| Category: Inflammation | ||||||
| 11/15/2023 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $780.65 | Research |
| Study: A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP, MUL | ||||||
| 11/15/2023 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $199.58 | Research |
| Study: A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP, MUL | ||||||
| 11/15/2023 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $81.11 | Research |
| Study: A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP, MUL | ||||||
| 11/15/2023 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $56.89 | Research |
| Study: A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP, MUL | ||||||
| 11/15/2023 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $40.14 | Research |
| Study: A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP, MUL | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP, MUL | GlaxoSmithKline, LLC. | $1,301 | 8 |
| A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Giant Cell Arteritis | SANOFI US SERVICES INC. | $1,220 | 14 |
| A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, | GlaxoSmithKline, LLC. | $1,153 | 7 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 83 | 103 | $43,019 | $8,531 |
| 2022 | 3 | 87 | 113 | $44,511 | $8,562 |
| 2021 | 4 | 96 | 118 | $42,739 | $9,410 |
| 2020 | 3 | 95 | 119 | $34,518 | $6,585 |
Total Patients
361
Total Services
453
Medicare Billing
$33,087
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 25 | 33 | $21,385 | $4,459 | 20.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 29 | 34 | $15,596 | $2,824 | 18.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 11 | $5,303 | $1,038 | 19.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 18 | 25 | $735.00 | $210.00 | 28.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 29 | 37 | $23,847 | $4,515 | 18.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 37 | 44 | $20,120 | $3,952 | 19.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 21 | 32 | $544.00 | $94.74 | 17.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 46 | 60 | $24,960 | $5,106 | 20.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 17 | 19 | $10,781 | $2,761 | 25.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 11 | 11 | $6,537 | $1,460 | 22.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 22 | 28 | $461.00 | $84.00 | 18.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 42 | 53 | $19,789 | $3,478 | 17.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 25 | 28 | $14,121 | $2,993 | 21.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 28 | 38 | $608.00 | $113.40 | 18.7% |
About Dr. Michael Bubb, MD
Dr. Michael Bubb, MD is a Rheumatology healthcare provider based in Gainesville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1770599094.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Bubb, MD has received a total of $18,664 in payments from pharmaceutical and medical device companies, with $2,880 received in 2024. These payments were reported across 107 transactions from 13 companies. The most common payment nature is "Travel and Lodging" ($9,026).
As a Medicare-enrolled provider, Bubb has provided services to 361 Medicare beneficiaries, totaling 453 services with total Medicare billing of $33,087. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Gainesville, FL
- Active Since 07/31/2006
- Last Updated 11/23/2011
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1770599094
Products in Payments
- COSENTYX (Biological) $1,860
- BENLYSTA (Biological) $1,467
- KEVZARA (Drug) $1,220
- SAPHNELO (Biological) $1,075
- Otezla (Drug) $495.19
- KRYSTEXXA (Drug) $112.94
- XOLAIR (Biological) $102.85
- Enbrel (Biological) $97.64
- Cimzia (Drug) $95.38
- CC-220 (Drug) $74.80
- TAVNEOS (Drug) $43.28
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Gainesville
N. Edwards, Md, MD
Rheumatology — Payments: $78,170
Rheumatology $78,170
Dina Hammad
Rheumatology — Payments: $61,680
Rheumatology $61,680
Ann Chauffe, Do, Mph, DO, MPH
Rheumatology — Payments: $57,166
Rheumatology $57,166
Marta Bognar, M.d, M.D
Rheumatology — Payments: $35,095
Rheumatology $35,095
Dr. William Chafin, M.d, M.D
Rheumatology — Payments: $26,601
Rheumatology $26,601
Brent Flickinger, Md, MD
Rheumatology — Payments: $22,111
Rheumatology $22,111